Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)
Results of 31 controlled randomized studies of insulin glargine given to patients with diabetes mellitus are reviewed to evaluate the frequency of malignantneoplasms. 52 tumours were diagnosed in 45 (0.8%) patients on insulin glargine therapy and 48 tumors in 46 (0.9%) patients using other insulins(...
Saved in:
| Main Authors: | Marina Vladimirovna Shestakova, Irina Vladimirovna Glinkina |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2010-03-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6022 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01) -
Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
by: Elena Valer'evna Biryukova, et al.
Published: (2012-09-01) -
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014-12-01) -
Development and Validation of Approach for the Detection of Neutralizing Antibodies Against Insulin (Glargine) in Human Blood Plasma
by: N. B. Abramenko, et al.
Published: (2019-09-01) -
Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database
by: Tongtong Wang, et al.
Published: (2025-04-01)